Pathways for aberrant angiogenesis in pancreatic cancer

被引：129

作者：

M Korc

机构：

[1] Div. of Endocrinol. Diabetes/Metab., Department of Medicine, University of California, Irvine

来源：

关键词：

Vascular Endothelial Growth Factor; Pancreatic Cancer; Hepatocyte Growth Factor; Pancreatic Cancer Cell; Pancreatic Cancer Cell Line;

D O I：

10.1186/1476-4598-2-8

中图分类号：

学科分类号：

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease. © 2003 Korc; licensee BioMed Central Ltd.

引用

页数：8

共 145 条

[91]

Fong T.A., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res., 59, 1, pp. 99-106, (1999)

[92]

Witte L., Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy, Cancer Metastasis Rev., 17, 2, pp. 155-161, (1998)

[93]

Seo Y., High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma, Cancer, 88, 10, pp. 2239-2245, (2000)

[94]

Ikeda N., Prognostic significance of angiogenesis in human pancreatic cancer, Br. J. Cancer, 79, pp. 9-10, (1999)

[95]

Ellis L.M., Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma, Eur. J. Cancer, 34, 3, pp. 337-340, (1998)

[96]

Balaz P., Friess H., Buchler M.W., Growth factors in pancreatic health and disease, Pancreatology, 1, 4, pp. 343-355, (2001)

[97]

Itakura J., Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer, Int. J. Cancer, 85, 1, pp. 27-34, (2000)

[98]

von Marschall Z., De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop, Gastroenterology, 119, 5, pp. 1358-1372, (2000)

[99]

Hotz H.G., Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth, J. Gastrointest. Surg., 5, 2, pp. 131-138, (2001)

[100]

Tokunaga T., Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line, Int. J. Oncol., 21, 5, pp. 1027-1032, (2002)

← 5 6 7 8 9 10 11 12 13 14 →